Dashboard
Manage Tickers

IMMPIMMUTEP Ltd

Nasdaq immutep.com


$ 1.90 $ -0.07 (-3.3 %)    

Thursday, 27-Jun-2024 13:44:36 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 481.76 $ 1.78 (0.37 %)
DIA $ 392.19 $ 1.40 (0.36 %)
SPY $ 546.18 $ 0.70 (0.13 %)
TLT $ 93.65 $ 0.22 (0.24 %)
GLD $ 215.04 $ 0.33 (0.15 %)
$ 2.77
$ 1.97
$ 1.89 x 100
$ 1.91 x 100
$ 1.66 - $ 2.02
$ 1.58 - $ 3.34
224,154
na
328.88M
$ 0.71
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

levi-strauss-posts-mixed-results-joins-walgreens-aerovironment-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
Levi Strauss Posts Mixed Results, Joins Wa...
06/27/2024 12:33:51

baird-maintains-outperform-on-immutep-lowers-price-target-to-6
Baird Maintains Outperform on Immutep, Low...
06/27/2024 11:09:35

Baird analyst Joel Beatty maintains Immutep (NASDAQ:IMMP) with a Outperform and lowers the price target from $7 to $6.

immutep-and-cardiff-university-sign-exclusive-license-for-next-generation-anti-lag-3-molecules-for-cancer
Immutep And Cardiff University Sign Exclus...
06/25/2024 12:14:11

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company d...

trading-halt-halt-status-updated-at-70000-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:00:...
06/05/2024 11:00:05

trading-halt-halted-at-35850-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 3:58:50 a.m. ET - ...
06/03/2024 07:58:54

reported-earlier-immutep-teams-up-with-msd-to-test-efti-and-keytruda-combination-in-phase-iii-non-small-cell-lung-cancer-trial
Reported Earlier, Immutep Teams Up With MS...
06/03/2024 05:45:56

Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD's anti-PD-1 therapy, and standard chemothera...

capital-one-initiates-coverage-on-immutep-with-overweight-rating-announces-price-target-of-10
Capital One Initiates Coverage On Immutep ...
05/17/2024 15:13:45

Capital One analyst Naureen Quibria initiates coverage on Immutep (NASDAQ:IMMP) with a Overweight rating and announces Price...

earlier-immutep--data-from-safety-lead-in-phase-of-aipac-003-confirmed-complete-response-in-a-patient-with-metastatic-breast-cancer-refractory-to-several-lines-of-therapy-achieved-during-combination-treatment-with-90mg-efti-and-paclitaxel
Earlier: Immutep Data From Safety Lead-in...
05/15/2024 09:17:49

– Immutep Limited ((ASX: IMM, NASDAQ:IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing nove...

initial-clinical-data-reported-from-immuteps-efti-combined-with-radiotherapy-and-checkpoint-inhibitor-from-phase-ii-trial-in-soft-tissue-sarcoma
Initial Clinical Data Reported From Immute...
05/02/2024 12:07:35

Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial e...

immutep-reported-cash-cash-equivalent-balance-of-954m-as-of-march-31-2024-giving-it-expected-cash-reach-into-early-cy2026
Immutep Reported Cash, Cash Equivalent Bal...
04/29/2024 09:24:22

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
04/24/2024 16:31:39

why-australian-cancer-biotech-firm-immutep-stock-is-soaring-on-wednesday
Why Australian Cancer Biotech Firm Immutep...
04/24/2024 14:43:20

Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients...

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
04/24/2024 12:06:37

immutep-announced-tuesday-data--from-efti-in--combination--with-keytruda-in--first--line-head--and--neck--squamous--cell--carcinoma-patients-who-do-not-express-pd-l1-shows-a-preliminary-269-response-rate-the-primary-endpoint-of-the-study
Immutep Announced Tuesday, Data From Efti...
04/24/2024 09:42:00

 Immutep Limited ((ASX: IMM, NASDAQ:IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...

immutep-appoints-leading-research-institute-to-conduct-first-in-human-phase-i-study-of-imp761
Immutep Appoints Leading Research Institut...
04/18/2024 12:07:32

Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody de...

Core News & Articles
Immutep Announced Tuesday, Positive Feedba...
04/17/2024 09:20:38

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...

cancer-focused-immuteps-stock-soars-on-tuesday---heres-why
Cancer Focused Immutep's Stock Soars On Tu...
03/05/2024 20:57:30

Immutep releases promising safety and efficacy data for 90mg eftilagimod alpha combined with paclitaxel in HR+/HER2- metastatic...

immutep-announces-first-clinical-data-from-90mg-dosing-of-efti
Immutep Announces First Clinical Data From...
03/05/2024 13:12:42

Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well toleratedEn...

immutep-q2-2024-cash-and-cash-equivalent-1037m
Immutep Q2 2024 Cash And Cash Equivalent ~...
01/30/2024 13:14:45

first-patient-dosed-in-trial-evaluating-efti-and-the-anti-pd-l1-therapy-bavencio-in-metastatic-urothelial-cancer
First Patient Dosed In Trial Evaluating Ef...
01/04/2024 13:17:06

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company d...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)